东西方前列腺癌的遗传差异

国际肿瘤学杂志››2014,Vol. 41››Issue (2): 120-123.doi:10.3760/cma.j.issn.1673-422X.2014.02.013

张延玲, 任国平

310003 杭州，浙江大学医学院附属第一医院病理科

收稿日期:2013-09-11修回日期:2013-12-04出版日期:2014-02-08发布日期:2014-01-26
通讯作者:任国平，E-mail: gpren2002@163.com E-mail:gpren2002@163.com
基金资助:

国家高技术研究发展计划（863计划）项目(2012AA022705)

Genetic differences of prostate cancer between Eastern and Western population

Zhang Yanling, Ren Guoping

Department of Pathology, First Affiliated Hospital of Zhejiang University Medical College, Hangzhou 310003, China

Received:2013-09-11Revised:2013-12-04Online:2014-02-08Published:2014-01-26
Contact:Ren Guoping E-mail:gpren2002@163.com

摘要/Abstract

摘要：前列腺癌在东西方人群中的发病率和死亡率有明显的种族和地区差异，其主要原因之一是遗传因素。为进一步探索东西方前列腺癌发生发展的不同机制，选取前列腺癌的易感基因RNASEL、ELAC2、PTEN、MSR1及TMPRSS2ERG，并主要以西班牙白种人、非裔美国人、欧洲人及中国人、日本人为代表，比较分析东西方人群基因型及等位基因的分布差异。

张延玲, 任国平. 东西方前列腺癌的遗传差异[J]. 国际肿瘤学杂志, 2014, 41(2): 120-123.

Zhang Yanling, Ren Guoping. Genetic differences of prostate cancer between Eastern and Western population[J]. Journal of International Oncology, 2014, 41(2): 120-123.

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］.CA Cancer J Clin, 2011, 61(2):69-90. ［2］ Klein EA, Silverman R. Inflammation, infection, and prostate cancer［J］. Curr Opin Urol, 2008, 18(3):315-319. ［3］ Robbins CM, Hernandez W, Ahaghotu C, et al. Association of HPC2/ELAC2 and RNASEL nonsynonymous variants with prostate cancer risk in African American familial and sporadic cases［J］. Prostate, 2008, 68 (16):1790-1797. ［4］ Rennert H, ZeiglerJohnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men［J］. Cancer Epidemiol Biomarkers Prev, 2005, 14(4):949-957. ［5］ Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans［J］. Clin Cancer Res, 2007, 13(19):5959-5964. ［6］ Nakazato H, Suzuki K, Matsui H, et al. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population［J］. Br J Cancer, 2003, 89(4):691-696. ［7］ Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p［J］. Nat Genet, 2001, 27(2):172-180. ［8］ Wang L, McDonnell SK, Elkins DA, et al. Role of HPC2/ELAC2 in hereditary prostate cancer［J］. Cancer Res, 2001, 61(17):6494-6499. ［9］ Xu B, Tong N, Li JM, et al. ELAC2 polymorphisms and prostate cancer risk: a metaanalysis based on 18 casecontrol studies［J］. Prostate Cancer Prostatic Dis, 2010, 13(3):270-277. ［10］ Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis［J］. Cancer Res, 2010, 70(13):5207-5212. ［11］ Liu W, Chang B, Sauvageot J, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100KSNP mapping array［J］. Genes Chromosomes Cancer, 2006, 45(11):1018-1032. ［12］ Haiman CA, Stram DO, Cheng I, et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer［J］. Cancer Epidemiol Biomarkers Prev, 2006, 15(5):1021-1025. ［13］ Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk［J］. Nat Genet, 2002, 32(2):321-325. ［14］ Seppl EH, Ikonen T, Autio V, et al. Germline alterations in MSR1 gene and prostate cancer risk［J］. Clin Cancer Res, 2003, 9(14):5252-5256. ［15］ Sun J, Hsu FC, Turner AR, et al. Metaanalysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk［J］. Prostate, 2006, 66(7):728-737. ［16］ Ren S, Peng Z, Mao JH, et al. RNAseq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancerassociated long noncoding RNAs and aberrant alternative splicings［J］. Cell Res, 2012, 22(5):806-821. ［17］ Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2ERG fusion prostate cancer among men undergoing prostate biopsy in the United States［J］. Clin Cancer Res, 2009, 15(14):4706-4711. ［18］ Miyagi Y, Sasaki T, Fujinami K, et al. ETS familyassociated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples［J］. Mod Pathol, 2010, 23(11):1492-1498. ［19］ MagiGalluzzi C, Tsusuki T, Elson P, et al. TMPRSS2ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, AfricanAmerican and Japanese patients［J］. Prostate, 2011, 71(5):489-497. ［20］ Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusionassociated deletions provide insight into the heterogeneity of prostate cancer［J］. Cancer Res, 2006, 66(17): 8337-8341. ［21］ Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2ERG gene fusion is associated with low Gleason scores and not with highgrade morphological features［J］. Mod Pathol, 2010, 23(10):1325-1333. ［22］ Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort［J］. Oncogene, 2007, 26(31):4596-4599. ［23］ Winnes M, Lissbrant E, Damber JE, et al. Molecular genetic analyses of the TMPRSS2ERG and TMPRSS2ETV1 gene fusions in 50 cases of prostate cancer［J］. Oncol Rep, 2007, 17(5):1033-1036. ［24］ Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome［J］. Mod Pathol, 2008, 21(12):1451-1460. ［25］ Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2ERG gene fusion is not associated with outcome in patients treated by prostatectomy［J］. Cancer Res, 2009, 69(4):1400-1406.

[1]	赵鑫, 范学武, 田龙, 胡逸民.三维超声在前列腺癌图像引导放疗中的应用与评价研究[J]. 国际肿瘤学杂志, 2024, 51(1): 43-49.
[2]	金明, 甄书青, 王彦巧, 申红霞, 张爱民, 回丽妹.丙泊酚对前列腺癌DU145细胞恶性生物学行为的影响及其机制[J]. 国际肿瘤学杂志, 2022, 49(8): 453-458.
[3]	张永丽, 张若佳, 范焕彩, 葛鲁娜, 王林.TXNDC5-Prx2途径对前列腺癌细胞耐药性的调控[J]. 国际肿瘤学杂志, 2021, 48(8): 473-478.
[4]	杜霄, 周菊英.局限性前列腺癌的立体定向放疗[J]. 国际肿瘤学杂志, 2021, 48(5): 313-316.
[5]	张小飞, 胡建鹏, 崔飞伦.长非编码RNA在前列腺癌中的作用机制[J]. 国际肿瘤学杂志, 2021, 48(2): 117-120.
[6]	刘振华.前列腺癌治疗的最新进展:肿瘤精准治疗时代下转移性去势抵抗性前列腺癌患者的管理[J]. 国际肿瘤学杂志, 2021, 48(11): 702-704.
[7]	郝雪燕, 刘风玲.复发难治性实体瘤NTRK靶向治疗新策略[J]. 国际肿瘤学杂志, 2020, 47(7): 423-427.
[8]	吉春冬, 刘凯, 冯越, 汪飞, 杨军, 薛荣波.PSAMR联合PI-RADS v2评分对高级别前列腺癌的预测价值[J]. 国际肿瘤学杂志, 2020, 47(12): 723-727.
[9]	张佳伟, 吴建臣.外泌体在前列腺癌中的应用[J]. 国际肿瘤学杂志, 2020, 47(10): 634-636.
[10]	徐耀宗, 顾晓, 王飞, 丁雪飞.雄激素剥脱治疗后前列腺癌发展为去势抵抗性前列腺癌的分子机制[J]. 国际肿瘤学杂志, 2018, 45(8): 506-509.
[11]	孙丹, 辛彦.卷曲螺旋结构域6与肿瘤[J]. 国际肿瘤学杂志, 2018, 45(5): 281-284.
[12]	黎立喜,马飞.早发性乳腺癌的临床特征及遗传易感基因[J]. 国际肿瘤学杂志, 2018, 45(4): 241-244.
[13]	毕泗成，刘浩，张鹏，李喆，买铁军，祝志臻.血清LCN2与PSA联合检测对前列腺癌的诊断价值[J]. 国际肿瘤学杂志, 2018, 45(1): 27-.
[14]	黄耿，姜卫东，毛青，桂定文.微小RNA-206通过干扰CDK4和GAK的表达对前列腺癌细胞生长的影响[J]. 国际肿瘤学杂志, 2017, 44(7): 485-489.
[15]	周启东，蒋光亮，徐可.糖皮质激素受体在泌尿系统恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(6): 476-.